Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.
Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.